

**EVENTO FORMATIVO RESIDENZIALE:
"WIKI PROSTATE CASES"
BOLOGNA 5 DICEMBRE 2023
n. ECM 106- 390370**

INFORMAZIONI DI DETTAGLIO SUL PROGRAMMA FORMATIVO

TIPOLOGIA EVENTO E ACCREDITAMENTO

Evento Residenziale (RES). Accreditamento Nazionale

DATA E LOCATION

BOLOGNA 5 dicembre 2023- Hotel NH De La Gare, Piazza XX Settembre 2

RAZIONALE

Il tumore della prostata rappresenta la forma di cancro più frequente nell'uomo nei Paesi Occidentali. Negli ultimi anni in Italia i casi di tumore della prostata hanno registrato un forte aumento, portando nel 2022 le nuove diagnosi a 40.500, con un incremento di circa il 16% rispetto allo stesso dato del 2017. Le cause di questo incremento sono molteplici ed il progressivo invecchiamento della popolazione gioca un ruolo importante in questo fenomeno di crescita che, secondo le proiezioni elaborate dall'Agenzia Internazionale per la Ricerca sul Cancro, continuerà fino al 2040.

Nel 2021 i decessi causati dal tumore della prostata sono stati oltre 7.200, mentre la sopravvivenza netta a 5 anni dalla diagnosi si attesta intorno al 91% dei casi. Questa forma di tumore occupa infatti il terzo posto nella scala della mortalità per cancro, soprattutto per gli uomini che hanno superato i 70 anni.

Per i pazienti che ricevono una diagnosi in fase precoce e per quelli che hanno una lenta progressione della malattia le possibilità di cura sono elevate, ma la sfida più delicata rimane quella del tumore della prostata metastatico, spesso molto aggressivo.

Le strategie terapeutiche per la cura di questa patologia variano a seconda dello stadio di malattia, e comprendono la chirurgia, la chemioterapia e la deprivazione androgenica impiegata sia nei casi di malattia localmente avanzata che in quelli di malattia metastatica. Il trattamento di deprivazione androgenica, pur essendo una strategia efficace, può andare incontro nel tempo ad una perdita di efficacia per lo sviluppo di resistenze al trattamento: una fase di malattia definita come "tumore della prostata resistente alla castrazione", la forma di neoplasia prostatica risulta più difficile da curare. Recenti progressi della ricerca uniti all'analisi molecolare della malattia hanno tuttavia permesso di contrastare alcune di queste forme resistenti alla castrazione con nuove strategie terapeutiche.

In questo complesso quadro si rende necessario un aggiornamento continuo dei clinici che, sulla scia delle più recenti acquisizioni scientifiche, possano approfondire i quesiti clinici più frequenti e rilevanti nella cura di questi pazienti, dal ruolo della diagnostica alla scelta del trattamento terapeutico più appropriato, avendo come obiettivo il miglioramento del decorso della malattia, soprattutto in quelle forme più complesse, con uno sguardo attento anche alla migliore qualità di vita possibile per i pazienti.

Partire dalla pratica clinica per costruire e condividere attivamente casi clinici simulati e la loro gestione, è la strategia formativa originale scelta per questo corso: un metodo di formazione e comunicazione interattiva, coinvolgente e qualificante.

PROGRAMMA

DURATA	RELAZIONE	RELATORE
13.45 – 14.00	Introduzione e presentazione obiettivi didattici del corso	S. Bracarda
MODERATORI: C. Ciccarese , C. Masini		
14.00 – 14.30	Primo caso clinico: simulazione individuale	
14.30 – 15.45	Primo caso clinico: elaborazione e discussione dei risultati	Relatore: G. Mammone Discussant: G. Zago
15.45 – 16.00	Analisi dei punti chiave del primo caso clinico	G. Zago
16.00 – 16.30	Secondo caso clinico: simulazione individuale	
16.30 – 16.45	Pausa lavori	
16.45 – 18.00	Secondo caso clinico: elaborazione e discussione dei risultati	Relatore: C. Messina Discussant: C. Cattrini
18.00 – 18.15	Analisi dei punti chiave del secondo caso clinico	C. Cattrini
18.15 – 18.30	Conclusioni e take home messages	S. Bracarda
18.30 – 18.45	Questionario ECM	

COERENZA CON L'OBIETTIVO NAZIONALE

Coerenza Obiettivo Nazionale N° 2: Linee guida – Protocolli – Procedure

DESTINATARI

Il percorso formativo è rivolto a Medici Chirurghi specializzati in:

- Oncologia
- Urologia
- Radioterapia

NUMERO CREDITI ECM ASSEGNATI

All'evento sono stati assegnati 6,4 crediti ECM.

FACULTY (in ordine alfabetico)

BRACARDA	SERGIO	RESP. SCIENTIFICO	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia, Urologia AFFILIAZIONE: Direttore struttura complessa di Oncologia medica e traslazionale e del dipartimento di Oncologia, Azienda Ospedaliera Santa Maria di Terni
CATTRINI	CARLO	RELATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia medica AFFILIAZIONE: S.C.D.U. Oncologia A.O.U. Maggiore della Carita, Novara
CICcarese	CHIARA	MODERATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia medica AFFILIAZIONE: Dirigente medico Oncologia Policlinico Universitario Gemelli IRCCS - Roma
MAMMONE	GIULIA	RELATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Specializzanda in Oncologia medica AFFILIAZIONE: Policlinico Umberto I Sapienza Università di Roma
MASINI	CRISTINA	MODERATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia medica AFFILIAZIONE: Dirigente medico oncologia AUSL Reggio Emilia

MESSINA	CARLO	RELATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia medica AFFILIAZIONE: Dirigente medico oncologia ARNAS Ospedale Civico Palermo
ZAGO	GIULIA	RELATORE	LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Oncologia medica AFFILIAZIONE: Dirigente medico UO Oncologia Ospedale di Treviso

DATI PROVIDER

Accreditamento Provider: PKG srl con decorrenza dal 15/10/2012 è Provider Standard **Nazionale** con numero **identificativo 106** dopo aver ottenuto il parere positivo dalla Commissione Nazionale per la Formazione Continua. Tale accreditamento è valido per un periodo di 4 anni ai sensi dell'Accordo stipulato in sede di Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano in data 5 novembre 2009 e del suo Regolamento Applicativo approvato dalla Commissione Nazionale per la Formazione Continua in data 13/01/2010 e successive modifiche del 19 aprile 2012. PKG s.r.l. è inoltre certificata UNI EN ISO 9001:2015 per la progettazione ed erogazione di servizi di formazione continua in medicina come provider ECM (Certificato TUV 50 100 9892)

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **BRACARDA SERGIO**
Address **S.C. OF MEDICAL ONCOLOGY, DEPARTMENT OF ONCOLOGY, AZIENDA
OSPEDALIERA S.MARIA, TERNI, VIALE TRISTANO DI JOANNUCCIO 1; 05100
TERNI, ITALY**
C.F.
Telephone
Fax
E-mail
Nationality Italian
Date of birth July 11, 1955

WORK EXPERIENCE

From August 2018 Head of the Medical Oncology Unit, Department of Oncology, Azienda
Ospedaliera S. Maria, Terni; Italy
2014 - 2018 Head of the Department of Oncology, USL-8 Arezzo (and, from 2016,
of the new larger USL Toscana Sud-Est), Istituto Toscano Tumori
(ITT), Italy
2009 - 2018 Head of the Medical Oncology Unit, Department of Oncology, Ospedale
San Donato, USL-8 Arezzo, Istituto Toscano Tumori (ITT), Italy
1999 - 2009 Senior Oncologist and Section Chief of Oncology-Urology in the
Medical Oncology Division, Policlinico Hospital, Perugia;
1996 -1999 Senior Registrar/Consultant Oncologist in the Department of Urology,
Perugia University;
1993 -1995 Junior Registrar/Consultant Oncologist in the Department of Urology,
Perugia University; Postgraduate School in Urology
1986 -1992 Resident in the Department of Medical Oncology of Perugia

Name and address of employer Az. Ospedaliera S. Maria, Viale Tristano di Joannuccio 1, Terni; Italy
• Type of business or sector Medical Oncology
• Occupation or position held Director: Medical Oncology

- Main activities and responsibilities

Main fields of research in treatment of:

Advanced Prostate Cancer
 Advanced Renal Cell Carcinoma
 Locally advanced and metastatic Urothelial Cancer
 CNS tumours
 Immunotherapy, targeted agents and other Innovative anticancer treatments
 Treatment personalization approaches
 Biological and chemotherapy combination treatment approaches,
 Pharmacogenomics

EDUCATION AND TRAINING

1999 University of Perugia, School of Medicine, Specialization in Urology cum laude

1991 Sacred Heart Catholic University of Rome, School of Medicine, Specialist in Medical Oncology cum laude

1986 University of Perugia, School of Medicine, Medical Degree cum laude

- Name and type of organisation providing education and training
 - Principal subjects/occupational skills covered

University of Perugia
Sacred Heart Catholic University of Rome

- Title of qualification awarded
 - Level in national classification (if appropriate)

Medical Degree in Medicine; two Specializations: Medical Oncology and Urology

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills
- Writing skills
- Verbal skills

VERY GOOD
 VERY GOOD
 VERY GOOD

TECHNICAL SKILLS
AND COMPETENCES
*With computers, specific
kinds of equipment,
machinery, etc.*

NORMALLY USING PERSONAL COMPUTER PROGRAMS, ESPECIALLY
MICROSOFT OFFICE (WORD, EXCEL POWER POINT, OUTLOOK), INTERNET
AND MAILING UTILITIES

ADDITIONAL INFORMATION

At the moment **143** publications (plus more than 500 abstracts) in peer-reviewed journals. One text on "Informed consent in Oncology and Hemato-Oncology", some chapters about issues of genitourinary oncology in published textbooks.

Active Member of:

- American Association for cancer research (**AACR**)
- American Society of Clinical Oncology (**ASCO**)
- European Society for Medical Oncology (**ESMO**)
- European Association of Urology (**EAU**)
- Italian Society of Medical Oncology (**AIOM**)
- Italian Society for Urology-Oncology (**SIUrO**)
- Italian Society of Urology (**SIU**)

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della L. 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996. Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

ANNEXES

Terni, July 4, 2019



Carlo Cattrini



Work experience

Consultant Medical Oncologist Sept 2020-present

Academic Division of Oncology – Clinic of Genito-Urinary Tumors, “Maggiore della Carità” University Hospital – University of Piemonte Orientale (UPO), Novara (Italy)

Description: I work as medical oncologist to manage patients with prostate, bladder, renal, penile and testicular cancers. I am principal and sub-investigator of several sponsored and academic studies involving patients with genito-urinary neoplasms. I am also involved in preclinical and translational studies to identify biomarkers of prognosis and resistance to therapies in patients with prostate cancer. I support many academic collaborations between the University of Piemonte Orientale (UPO) in Novara, the University of Genoa, the Biomedical Research Institute of Málaga (IBIMA) and the Spanish National Cancer Research Center of Madrid.

PhD student in Translational Oncology Nov 2019-Nov 2022

University of Genoa, Genoa (Italy)

- *Description:* Title of the project: BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).

ESMO Clinical Research Fellow 2019-2020

Prostate Cancer Clinical Research Unit, *Dr D. Olmos*, National Cancer Research Center - CNIO, Madrid (Spain)

- *Description:* I was awarded with the 2019 ESMO Clinical Research Fellowship to work as Co-Investigator of the international multicentre BRCA2men project, which aims at validating the germline BRCA2 mutation as a predictive biomarker to select the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). I also collaborated with translational studies on DNA damage and response genes and prostate cancer at CNIO Prostate Cancer Team.

Resident in Medical Oncology 2014 –2019

Academic Unit of Medical Oncology, *Prof F. Boccardo*, IRCCS Ospedale Policlinico San Martino, Genoa (Italy)

- *Description:* I was involved both in translational research and clinical activity, focused on genitourinary neoplasms. I worked on a project on AR-V7 and circulating tumor cells in patients with prostate cancer. I was also involved in the design and carrying out of several non-commercial preclinical (in vitro pharmacology and proteomic experiments) and clinical studies (i.e., liquid biopsies in genitourinary tumours, role of periostin expression in prostate cancer), working passionately with my colleagues and with other Units (Pathologists, Statisticians, Lab Team). I also participated in revising the Italian National Guidelines on Prostate Cancer (AIOM), interacting with other Italian and European centers of excellence.

Researcher (postgraduate research grant) 2013 –2014

Cytometry Unit – Laboratory of Cancer Pharmacology – Department of Oncology, *Prof M. D’Incalci*, IRCCS "Mario Negri" Institute for Pharmacological Research, Milan (Italy)

- *Description:* I learned about basic laboratory techniques (cell cultures, cell vitality/mortality tests, flow cytometry, pharmacological tests, immunohistochemistry, cytological staining, immunofluorescence). I collaborated with the research study: "Analysis of the antitumor activity of trabectedin in myelodysplastic / myeloproliferative diseases".

Internship in Medical Oncology 2012 – 2014

Medical Oncology Unit, *Prof. A. Riccardi*, IRCCS "Salvatore Maugeri" Foundation, Pavia (Italy)

- *Description:* I took care of patients with different solid and hematologic neoplasms. I followed the research programs on breast cancer at the Laboratory of Experimental Oncology and Pharmacogenomics. I collaborated with the studies "Evaluation of circulating tumor cells and circulating endothelial progenitors in patients with breast cancer" and "Trabectedin and indole-3-carbinol in the treatment of metastatic breast cancer".

Congresses and courses

- Scientific committee chair of the **2022 Young Onco-GU international meeting** (<https://fad.accmed.org/course/info.php?id=750>).
- Admitted to the prestigious 2019 Workshop on Methods in Clinical Cancer Research (MCCR) in Zeist.
- Participant of several Italian and International Cancer Congresses (i.e, AIOM, ESMO, ASCO).
- Participant of several ESMO Preceptorship Courses (Cancer Immunology 2015, Prostate Cancer 2016, and Kidney-Bladder Cancer 2019).

- Participant of the 4 Courses on Methodology in Clinical Trials (Negrar, IT, 2017), of the advanced training courses on “Circulating rare cells” (2013), “Novel targets of cell therapy” (2014), and “The niches of the normal somatic and cancer stem cells” (2014) (Pavia, IT).

Education

University of Genoa – Specialist in Medical Oncology with full marks 12/2019

MEBEKO - Swiss Medical License 06/2018

University of Pavia – Italian Medical License 02/2013

University of Pavia – Master's degree in Medicine and Surgery with honours 28/09/2012

Experimental thesis "Trabectedin and indole-3-carbinol in the treatment of metastatic breast cancer: clinical trial of early stage"

Liceo Classico B. Cavalieri – Verbania – Diploma 2006

Prizes and awards

- Winner of the **2020 Conquer Cancer Foundation of ASCO Merit Award** with the Poster entitled “Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States” (2020 ASCO-GU Congress, San Francisco).
- Winner of the **2019 ESMO Clinical Research Fellowship** with the project “BRCA2MEN: an international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations in selecting first-line metastatic castration-resistant prostate cancer (mCRPC) treatment” (2019 ESMO Congress, Barcelona).
- Winner of the First Prize for the **Best Poster on Prostate Cancer** at the 9th European Multidisciplinary Congress on Urological Cancers (EMUC 2017, Barcelona).
- Winner of the annual **Research Grant** (2013-2014 Collegio Ghislieri, Pavia).
- Winner of the "**Costa Foundation**" Prize (2013, University of Pavia) for the best thesis in oncology.
- Board Member of the Federation of Italian Cooperative Oncology Groups - Young Oncologist (FICOG-GO)
- Member of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Italian Network For Research In Urologic-Oncology (Meet-URO) and Associazione Italiana di Oncologia Medica (AIOM).

Personal skills

I speak Italian (mother language) English (*Occupational English Test 10/03/2018*. Reading B, Speaking B, Writing B, Listening C) and Spanish (intermediate). I've very good command of Microsoft Office tools and excellent digital competence. Good Clinical Practice (GCP) training certificate (13/10/2020).

Translational and clinical studies

I am/was **chief investigator or co-chief investigator** of the following studies:

- CAPNOVA: Clinical and molecular characterization study of Advanced Prostate cancer patients in NOVAra.
- Lipidomic profiling of patients with heavily pretreated castration-resistant prostate cancer.
- Prognostic and predictive value of CTC-derived AR-V7 in patients with advanced prostate cancer.
- Prognostic role of periostin overexpression in tumor biopsies from patients with prostate cancer.

I am/was **principal investigator (PI)** of the following studies:

- ARASENS: A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer.
- ARAMIS: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer.
- ARCHES: A multinational, phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC).
- SAKK 08/16: ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (MCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: a multicenter randomized double-blind placebo-controlled phase II trial protocol.
- SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer.
- TITAN: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC).

- THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.
- RESORT - ONC- RCC- 02: Studio randomizzato in aperto multicentrico di fase 2 teso a valutare l'efficacia di sorafenib in pazienti affetti da carcinoma avanzato del rene dopo resezione radicale delle metastasi.
- REASSURE: Radium-223 alpha emitter agent in safety study in mCRPC population for long term evaluation.
- BRCA2MEN: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).
- CO.I.ROS.: COvid 19 Infection in metastatic castration-resistant pROstate cancer patients.
- EXCALIBUR: A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
- EAP Avelumab: Single patient Compassionate Use Program with Avelumab for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
- TEAM: Trattamento con docEtaxel upfront nei pazienti Affetti da carcinoma prostatico Metastatico ormono-sensibile: analisi retrospettiva di una casistica multicentrica.
- BioChiP: A phase II, open-label, biomarker-guided study of Carboplatin efficacy in pretreated metastatic castration-resistant Prostate Cancer (mCRPC)

I am/was **subinvestigator (SI)** of the following studies:

- E.C.HO.S.: Evaluation of clinical outcomes of Chemotherapy combined to androgen deprivation therapy in HOrmone-Sensitive metastatic prostate cancer patients.
- MEMORIAE: Valutazione degli effetti cognitive in pazienti con tumour della prostata metastatico resistente alla castrazione trattati con abiraterone o enzalutamide.
- MA.RE.CA.P: Correlazione tra sviluppo di Macroцитosi ed outcome nei pazienti affetti da carcinoma Renale avanzato trattati con Cabozantinib e/o Pazopanib.
- I-RARE meet uro 3: Italian Registry on rAre genito-uRinary nEoplasms.

Publications

- Borgogna C, De Andrea M, Griffante G, Lai A, Bergna A, Galli M, Zehender G, Castello L, Ravanini P, **Cattrini C**, Mennitto A, Gennari A, Gariglio M. *SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response*. J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200.
- Buti S, Bersanelli M, Mazzaschi G, **Cattrini C**, Brunelli M, Maio MD. *Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis*. Immunotherapy. 2021 Nov 22. doi: 10.2217/imt-2021-0157.
- **Cattrini C**, Messina C, Airoidi C, Buti S, Roviello G, Mennitto A, Caffo O, Gennari A, Bersanelli M. *Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis*. Ther Adv Urol. 2021 Oct 29;13:17562872211053189.
- Bersanelli M, Buti S, Rizzo M, Cortellini A, **Cattrini C**, Massari F, Masini C, Vitale MG et al. *GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak*. Ther Adv Urol. 2021 Oct 22;13:17562872211054302.
- **Cattrini C**, España R, Mennitto A, Bersanelli M, Castro E, Olmos D, Lorente D, Gennari A. *Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer*. Cancers (Basel). 2021 Sep 8;13(18):4522
- Roviello G, Buti S, **Cattrini C**, Mennitto A, Messina C, Airoidi C, Vannini G, Bersanelli M. *Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?* Ther Adv Urol. 2021. doi: 10.1177/17562872211029784
- Biello F, Platini F, D'Avanzo F, **Cattrini C**, Mennitto A, Genestroni S, Martini V, Marzullo P, Aimaretti G, Gennari A. *Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights*. Biomolecules. 2021 Jan 19;11(1):125.
- Barranco R, Messina C, Bonsignore A, **Cattrini C**, Ventura F. *Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?* Front Public Health. 2020 Dec 18; 8:602988.
- Messina C, Salati M, Messina M, **Cattrini C**, Merz V, Caffo O. *Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials*. Eur J Clin Invest. 2020 Dec 31:e13483.
- Pedrazzoli P, Rondonotti D, **Cattrini C**, Secondino S, et al. *Metastatic Mediastinal Germ-Cell Tumor and Concurrent COVID-19: When Chemotherapy Is Not Deferrable*. Oncologist. 2020 Dec 20. doi: 10.1002/onco.13647.
- Cerbone L, **Cattrini C**, Vallome G, Latocca MM, Boccardo F, Zanardi E. *Combination therapy in metastatic renal cell carcinoma: Back to the future?* Semin Oncol. 2020 Dec;47(6):361-366.
- Lozano R, Castro E, Aragón IM, Cendón Y, **Cattrini C**, López-Casas PP, Olmos D. *Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer*. Br J Cancer. 2020 Oct 27. doi: 10.1038/s41416-020-01114-x.
- **Cattrini C**, Capaia M, Boccardo F, Barboro P. *Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study*. Cancer Treat Res Commun. 2020; 25:100221.
- **Cattrini C**, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, Messina C, Castro E, Olmos D, Boccardo F. *Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer*. Cancers (Basel). 2020 Oct 3;12(10): E2855.
- Messina C, **Cattrini C**, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. *BRCA Mutations in Prostate Cancer:*

Prognostic and Predictive Implications. J Oncol. 2020 Sep 7; 2020:4986365.

- **Cattrini C**, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F. *Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer.* Cancers (Basel). 2020 Aug 18;12(8):2325.
- **Cattrini C**, Barboro P, Rubagotti A, Zinoli L, Zanardi E, Capaia M, Boccardo F. *Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer.* Transl Oncol. 2020 Jul;13(7):100789.
- Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodríguez-Vida A, Lainez N, Villatoro R, Llácer C, **Cattrini C**, et al. PROREPAIR-B Study Investigators. *Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.* Eur Urol. 2020 Jun;77(6):763-766.
- Messina C, Messina M, **Cattrini C**. *From astrology to prostate cancer: what is the role of subgroup analyses?* Ann Oncol. 2020 Mar;31(3):437-438.
- **Cattrini C**, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F. *Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.* Cancers. 2019. 11(9):1365.
- **Cattrini C**, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D. *Current treatment options for metastatic hormone-sensitive prostate cancer.* Cancers. 2019. 11(9):1355.
- Vallome G, **Cattrini C**, Messina C, Boccardo F, Zanardi E. *Reduced dose of Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): from PROSELICA trial to the real life. A single institution experience.* Anticancer Drugs. 2019. 30(8):854-858.
- Zanardi E, Soldato D, Latocca MM, **Cattrini C**, Boccardo F. *To switch or not to switch? A real life experience using Dexamethasone in combination with Abiraterone.* Ther Adv Urol. 2019. 11:1756287219854908.
- **Cattrini C**, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Messina C, Zanardi E, Boccardo F. *Prognostic variables in patients with non-metastatic small cell neuroendocrine carcinoma of the bladder: a population-based study.* Clin Genitourin Cancer. 2019. 17(4):e724-e732.
- **Cattrini C**, Rubagotti A, Nuzzo PV, Zinoli L, Salvi S, Boccardo S, Perachino M, Cerbone L, Vallome G, Latocca MM, Zanardi E, Boccardo F. *Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.* Clin Genitourin Cancer. 2018. 16(6):e1257-e1265.
- Messina C, **Cattrini C**, Buzzatti G, Cerbone L, Zanardi E, Messina M, Boccardo F. *CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.* Breast Cancer Res Treat. 2018. 172(1):9-21.
- Capaia M, Granata I, Guarracino M, Petretto A, Inglese E, **Cattrini C**, Ferrari N, Boccardo F, Barboro P. *A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.* Int J Mol Sci. 2018. Jun 30;19(7).
- **Cattrini C**, Zanardi E, Boccardo F. *Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.* J Clin Oncol. 2018 Aug 1;36(22):2350.
- **Cattrini C**, Boccardo F. *Atezolizumab and bladder cancer: facing a complex disease.* Lancet. 2018. 391(10118):305-306
- Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, **Cattrini C**, Messina C, Boccardo F. *Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.* Ther Adv Med Oncol. 2018, Vol. 10: 1 – 15.
- Zanardi E, **Cattrini C**, Boccardo F. *Bone Metastases from Prostate Cancer: Hormonal Therapy.* In book: Bone Metastases from Prostate Cancer, pp.105-120, 2017, Springer.
- **Cattrini C**, Zanardi E, Vallome G, Cavo A, Cerbone L, Di Meglio A, Fabbroni C, Latocca MM, Rizzo F, Messina C, Rubagotti A, Barboro P, Boccardo F. *Targeting androgen-independent pathways: new chances for patients with prostate cancer?.* Critical Reviews in Oncology/Hematology. 2017; 118:42-53
- Messina C, Buzzatti G, Dellepiane C, Cavo A, Tolomeo F, **Cattrini C**, Boccardo F. *Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives.* Anticancer Drugs. 2016 Nov;27(10):917-43
- **Cattrini C**, Dellepiane C, Cavo A, Buzzatti G, Tolomeo F, Messina C, Boccardo F. *Immunotherapy for genitourinary cancer: state of the art and new perspectives.* Anticancer Drugs. 2016 Aug;27(7):585-99

Abstracts and Posters

- Biello F, Martini V, Branni C, Borra G, Genestroni S, Mennitto A, **Cattrini C** et al. 1777P HEME catabolism in peripheral monocytes and response to immune checkpoint inhibitors in advanced lung cancer. September 2021 Annals of Oncology 32:S1218.
- **Cattrini C**, Lozano R et al. *BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).* Ann Oncol (2020) 31(4), S547-S548.
- Llacer Perez C, Romero Laorden N, Lozano Mejorada R, Piulats JM, Puente J, Lorente Estelles D, Medina A, **Cattrini C** et al. 628P Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone. Annals of Oncology (2020) 31 (suppl_4): S507-S549. 10.1016/annonc/annonc275
- **Cattrini C**, Zanardi E et al. *Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States.* J Clin Oncol 38, no. 6_suppl (February 20, 2020) 48-48.
- **Cattrini C**, Romero-Laorden N et al. *Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.* Ann Oncol (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248

- **Cattrini C**, Capaia M, Boccardo F. *PO-445 The phenotypic plasticity of castration-resistant prostate cancer: from challenge to opportunity*. 10.1136/esmoopen-2018-EACR25.956. ESMO Open 2018;3:doi: 10.1136/esmoopen-2018-EACR25.956
- **Cattrini C**, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Buzzatti G, Vallome G, Rizzo F, Cavo A, Beshiri K, Soldato D, Messina C, Zanardi E, Boccardo F. *Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study*. J Clin Oncol 36, 2018 (suppl; abstr e16506)
- Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, **Cattrini C**, Messina C, Boccardo F. *Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes*. Ann Oncol. 2017, 28(suppl_6).
- Bruzzone M, Dellepiane C, Bo E, Cavo A, Giannelli F, Vellone VG, Zanardi E, Buzzatti G, Messina C, **Cattrini C**, Gustavino C, Boccardo F. *Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study*. J Clin Oncol 34, 2016 (suppl; abstr 5529).
- Romano M, Galli A, Panini N, Paracchini L, Beltrame L, Bello E, Licandro SA, **Cattrini C**, Tancredi R, Marchini S, Rosti V, Zecca M, Della Porta M, Zambelli A, Galmarini CM, Erba E, D'Incalci M. *Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemia*. European Journal of Cancer, 2014, 50(suppl6)
- Zambelli A, Tancredi R, Negri S, **Cattrini C**, Ponchio L, Frascaroli M, Da Prada GA, Fregoni V, Pavesi L, Riccardi A, Zucchetti M, Fuso Nerini I, D'Incalci M. *Trabectedin and indole-3-carbinol combination in heavily pre-treated metastatic breast cancer: Results of a pilot clinical study*. 50th Annual Meeting of the American-Society-of-Clinical-Oncology, 2014, Volume: 32
- Tancredi R, Negri S, **Cattrini C**, Ponchio L, Frascaroli M, Da Prada GA, Fregoni V, Pavesi L, Riccardi A, Zucchetti M, D'Incalci M and Zambelli A. *Safety profile and tolerability of Trabectedin and Indole-3-Carbinol combination in refractory advanced breast cancer*. Preliminary results of Phase 1 clinical study. The Breast, 2013. 22:S44

Carlo Cattrini

CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	CHIARA CICCARESE
E-mail	
Nazionalità	
Data di nascita	10/12/1985

ISTRUZIONE E FORMAZIONE

<ul style="list-style-type: none">• Date (da – a)• Nome e tipo di istituto di istruzione o formazione• Qualifica conseguita• Livello nella classificazione nazionale	<p>09/1999 - 06/2004 Liceo Classico G. Bagatta</p> <p>Maturità Classica Votazione finale 98/100</p>
<ul style="list-style-type: none">• Date (da – a)• Nome e tipo di istituto di istruzione o formazione• Principali materie / abilità professionali oggetto dello studio• Qualifica conseguita• Livello nella classificazione	<p>10/2004 - 03/2011 Università degli Studi di Brescia</p> <p>Corso di Laurea in Medicina e Chirurgia Tesi di Laurea: Identificazione, caratterizzazione e significato clinico delle cellule tumorali circolanti (CTC) nelle neoplasie avanzate del distretto testa-collo. Relatore: Prof. Piero Nicolai; Correlatore: Dott.ssa Edda Simoicini</p> <p>Medico Chirurgo 110/110 con lode</p>
<ul style="list-style-type: none">• Date (da – a)• Nome e tipo di istituto di istruzione o formazione• Principali materie / abilità professionali oggetto dello studio	<p>03/2008 – 03/2011 Università degli Studi di Brescia, Facoltà di Medicina e Chirurgia.</p> <p>Allieva Interna presso Unità Operativa di Oncologia Medica – Reparto di degenza, Spedali Civili di Brescia.</p>
<ul style="list-style-type: none">• Date (da – a)• Nome e tipo di istituto di istruzione o formazione• Principali materie / abilità professionali oggetto dello studio	<p>09/2011– 05/07/2012 Azienda Ospedaliera Universitaria Integrata Verona</p> <p>Allieva Interna presso Unità Operativa Complessa di Oncologia Medica – Reparto di degenza, Ospedale Policlinico “Giambattista Rossi” – Borgo Roma, Verona</p>
<ul style="list-style-type: none">• Date (da – a)• Nome e tipo di istituto di istruzione o formazione	<p>05/07/2012– 19/12/2017 Azienda Ospedaliera Universitaria Integrata Verona</p>
<ul style="list-style-type: none">• Principali materie / abilità professionali oggetto dello studio• Qualifica conseguita• Livello nella classificazione	<p>Medico in Formazione specialistica – Scuola di Specializzazione in Oncologia Medica (Direttore Prof. G. Tortora.</p> <p>Specializzazione in Oncologia Medica Tesi di specializzazione: Carcinoma Della Prostata Metastatico Alla Diagnosi: Stratificazione Prognostica e Caratterizzazione Genetica 50/50 e lode</p>

<ul style="list-style-type: none"> • Date (da – a) • Nome e tipo di istituto di istruzione o formazione 	12/2017 – 09/2018 Attività a carattere scientifico relative allo studio ARIES – Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona
<ul style="list-style-type: none"> • Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Principali materie / abilità professionali oggetto dello studio 	09/2018 – in corso Università Cattolica del Sacro Cuore, sede di Roma. Fondazione Policlinico Universitario Agostino Gemelli IRCCS PhD Student in Scienze Oncologiche
<ul style="list-style-type: none"> • Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Principali materie / abilità professionali oggetto dello studio 	06/2019 – in corso Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC di Oncologia Medica Medico Specialista con contratto Libero Professionale

CAPACITÀ E COMPETENZE PERSONALI

MADRELINGUA

ITALIANO

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

INGLESE
 Ottima
 Ottima
 Ottima

CAPACITÀ E COMPETENZE TECNICHE

BUONE COMPETENZE INFORMATICHE GENERALI.
 BUONA CONOSCENZA DEI PROGRAMMI: WORD, EXCEL, POWER POINT, INTERNET EXPLORER, OUTLOOK EXPRESS.


ALLEGATI

- Allegato al CV #1 [Pubblicazioni];
- Allegato al CV #2 [Congressi & Corsi di aggiornamento];
- Allegato al CV #3 [Relazioni & Presentazioni]
- Allegato al CV #4 [Studi Clinici]

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legislativo 196 del 30 giugno 2003 per le finalità di cui al presente avviso di candidatura.

Roma, il 07/11/2022

Chiara Ciccarese





Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Giulia Mammone**
Address(es)
Tax Code **MMMGLI92L62H501U**
Telephone number
E-mail
Nationality **Italiana**
Date of birth **22 Luglio 1992**

Work experience

Dates **Da Novembre 2022** Occupation or position held **rotazione extraformativa in qualità di medico in formazione specialistica nel reparto di "Oncologia Medica e Traslazionale" dell "Azienda Ospedaliera Santa Maria" Terni**

Dates **Da Novembre 2018** Occupation or position held **iscrizione al Corso di diploma della scuola di specializzazione in Oncologia Medica presso "Sapienza" Università di Roma, con servizio nella sede ospedaliera "Policlinico Umberto I"**

Dates **Aprile 2018 – Maggio 2018** Occupation or position held **Medico frequentatore presso Oncologia Medica del "Policlinico San Matteo" di Pavia**

Education and training

Dates **Agosto 2016-Novembre 2017**
Title of qualification awarded **Tirocinio in Oncologia Medica presso Policlinico Umberto I, Università "Sapienza" di Roma**

Dates **Settembre 2011-Luglio 2017**
Principal subjects/occupational skills covered **Laurea Magistrale a ciclo unico in Medicina e Chirurgia conseguita con votazione finale di 110 e lode/110**

Dates **September 2006-July 2011**
Title of qualification awarded **Diploma di Liceo Classico conseguito presso Liceo Anco Marzio con votazione finale di 100/100.**

Personal skills and competences

Mother tongue (s) -Italiano
Other language(s) -Inglese (livello B2)
European Level* -Francese (livello A2)

Publications

1. Botticelli, Andrea; Cirillo, Alessio; Pomati, Giulia; Cerbelli, Bruna; Scagnoli, Simone; Roberto, Michela; Gelibter, Alain; **Mammone, Giulia**; Calandrella, Maria Letizia; Cerbelli, Edoardo; Di Pietro, Francesca Romana; De Galitiis, Federica; Lanzetta, Gaetano; Cortesi, Enrico; Mezi, Silvia; Marchetti, Paolo. "The role of opioids in cancer response to immunotherapy". **J Transl Med. BioMed Central Ltd**, 2021, Vol. 19, Iss. 1 - ISSN: 1479-5876
2. Botticelli, Andrea; Mezi, Silvia; Pomati, Giulia; Sciattella, Paolo; Cerbelli, Bruna; Roberto, Michela; **Mammone, Giulia**; Cirillo, Alessio; Cassano, Alessandra; Di Dio, Carmela; Cortellini, Alessio; Pizzuti, Laura; Ronzino, Graziana; Salati, Massimiliano; Vici, Patrizia; Polimeni, Antonella; Carlo Merlano, Marco; Nuti, Marianna; Marchetti, Paolo. "The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial". **Vaccines**, 2020, Vol. 8, Iss. 2 - ISSN: 2076-393X
3. Botticelli A, Pomati G, Cirillo A, **Mammone G**, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, Catalano C, Vullo F, Della Monaca M, Amirhassankhani S, Tomao S, Valentini V, De Vincentiis M, Tombolini V, Della Rocca C, Polimeni A, di Gioia C, Corsi A, D'Amati G, Mezi S, Marchetti P. "Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era". **J Transl Med.** 2021 Jul 12;19(1):303.
4. Matteo Santoni 1, Javier Molina-Cerrillo 2, Zin W Myint 3, Francesco Massari 4 5, Tomas Buchler 6, Sebastiano Buti 7, Marc R Matrana 8, Ugo De Giorgi 9, Mimma Rizzo 10, Ignacio Ortego Zabalza 11, Luca Galli 12, Paolo Andrea Zucali 13, Gaetano Aurilio 14, Lorena Incorvaia 15, Maria Bassanelli 16, **Giulia Mammone** 17, Alessia Salfi 12, Luca Isella 7, Veronica Mollica 18 19, Enrique Grande 11, Camillo Porta # 10 20, Nicola Battelli # 1. "Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies". **Target Oncol.** 2022 Sep;17(5):571-581. doi: 10.1007/s11523-022-00907-9.
5. Matteo Santoni 1, Francesco Massari 2, Zin W Myint 3, Roberto Iacovelli 4, Martin Pichler 5, Umberto Basso 6, Jindrich Kopecky 7, Jakub Kucharz 8, Sebastiano Buti 9, Alessia Salfi 10, Thomas Büttner 11, Ugo De Giorgi 12, Ravindran Kanesvaran 13, Ondřej Fiala 14, Enrique Grande 15, Paolo Andrea Zucali 16, Giuseppe Fornarini 17, Maria T Bourlon 18, Sarah Scagliarini 19, Javier Molina-Cerrillo 20, Gaetano Aurilio 21, Marc R Matrana 22, Renate Pichler 23, Carlo Cattrini 24, Tomas Büchler 25, Emmanuel Seront 26, Fabio Calabrò 27, Alvaro Pinto 28, Rossana Berardi 29, Anca Zgura 30, **Giulia Mammone** 31, Jawaher Ansari 32, Francesco Atzori 33, Rita Chiari 34, Roubini Zakopoulou 35, Orazio Caffo 36, Giuseppe Procopio 37, Maria Bassanelli 38, Ilaria Zampiva 39, Carlo Messina 40, Zsófia Küronya 41, Alessandra Mosca 42, Dipen Bhuvra 43, Nuno Vau 44, Lorena Incorvaia 45, Sara Elena Rebuzzi 46, Giandomenico Roviello 47, Ignacio Ortego Zabalza 15, Alessandro Rizzo 48, Veronica Mollica 49, Ilaria Catalini 1, Fernando Sabino M Monteiro 50, Rodolfo Montironi 51, Nicola Battelli 1, Mimma Rizzo 52, Camillo Porta 53. "Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients with Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)". **Clinical Genitourinary Cancer** 2023. <https://doi.org/10.1016/j.clgc.2023.03.006>



Terni 04/07/2023

Il/la sottoscritto/a CRISTINA MASINI

è consapevole che in caso di dichiarazioni non veritiere, di formazione o uso di atti falsi verrà punito ai sensi del Codice Penale e delle Leggi speciali in materia così come previsto dall'art. 76 del D.P.R. n. 445/2000 e che, inoltre, qualora dal controllo effettuato emerga la non veridicità del contenuto delle dichiarazioni rese, decadrà dai benefici eventualmente conseguenti al provvedimento emanato sulla base della dichiarazione non veritiera - art. 75 del D.P.R. n. 445/2000.

Informazioni personaliNome(i) / Cognome(i) **Cristina Masini**

Indirizzo(i)

Telefono(i)

Fax

E-mail

Cittadinanza italiana

Data di nascita

Sesso femmina

**Occupazione desiderata/
Settore professionale****Oncologia****Esperienza
professionale****Lavoro o posizione
ricoperti**

Contrattista e assegnista di ricerca presso il Dipartimento integrato di Oncologia, Ematologia e Malattie dell'Apparato respiratorio dell'Università di Modena e Reggio Emilia da Agosto 2011 ad Agosto 2013. Contratto LP presso struttura semplice dipartimentale DH oncologico dal 16/08/2013 al 14/02/2014. Contratto libero professionale presso struttura complessa di Oncologia, IRCCS Arcispedale Santa Maria Nuova di Reggio Emilia dal 20/02/2014 al 19/06/2017. Dal 20/06/2017 dirigente medico Oncologia presso la struttura complessa di Oncologia, AUSL-IRCCS di Reggio Emilia

**Principali attività e
responsabilità**

Sub-investigator in più di 80 studi clinici di fase I, II, III nell'ambito dell'oncologia mammaria, ginecologica ed urologica. Principal investigator in più di 15 trials clinici di fase II e III

**Nome e indirizzo del datore di
lavoro**

S.C. Oncologia, AUSL- IRCCS Reggio Emilia

Tipo di attività o settore

Oncologia

Istruzione e formazione

2000 diploma di maturità presso il Liceo Scientifico Lazzaro Spallanzani Reggio Emilia
2006 laurea in Medicina e Chirurgia presso Università di Modena: votazione 110/110
2007 Abilitazione all'esercizio della professione di medico chirurgo
2011 Diploma di specializzazione in Oncologia ad indirizzo in Oncologia Medica presso l'Università di Modena e Reggio Emilia: votazione 110/110 lode

**Capacità e competenze
personali**

Madrelingua(e) italiana

Altra(e) lingua(e)

Autovalutazione

Livello europeo (*)

inglese

tedesco

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
buono	buona	intermedia	intermedia	buono
elementare	elementare	elementare	elementare	intermedio

Capacità e competenze informatiche	Utilizzo avanzato del pacchetto office
Conoscenze metodologiche	Buona conoscenza della metodologia SIGN e GRADE.
Pubblicazioni in volumi	<ul style="list-style-type: none"> - Studio osservazionale "Il dolore nei pazienti con cancro "Risultati preliminari: Boll Soc Med Chir Modena. Anno 122- N. 1-3, gennaio-giugno 2007. Dini D., Iacchetta F., Pagano M., Postiglione R., Masini C., Malavasi N., Piccinini L. - Hospice ospedaliero del centro oncologico: attività dal 1/09/2006 al 31/08/2007: Boll Soc Med Chir Modena. Anno 122- N. 1-3, gennaio-giugno 2007. Dini D., Giovannelli S., Malavasi N., De Matteis E., Ferrari A., Cervo G., Iacchetta F., Sternieri R., Pagano M., Postiglione R., Fontana A., Giardina D., Masini C., Piccinini L. - Hospice ospedaliero: non solo "end of life care" ma anche simultaneous care. Boll Soc Med Chir Modena. Anno 123- N. 1-3, gennaio-giugno 2008. Dini D., Malavasi N., De Matteis E., Ferrari A., Cervo G., Iacchetta F., Sternieri R., Pagano M., Postiglione R., Fontana A., Giardina D., Masini C., Piccinini L. - Hospice ospedaliero del centro oncologico: attività dal 1/01/2008 al 31/07/2008: Boll Soc Med Chir Modena Anno 123- N. 1-3, gennaio-giugno 2008. Dini D., Masini C., Barbieri E., Dieci M.V., Scarabelli L., Piccinini L. - La gestione presso l'hospice ospedaliero dei pazienti in terapia oncologica attiva ("simultaneous care"). Analisi del periodo 1/1/2008 – 30/06/2009: Boll Soc Med Chir Modena, Anno 124 – N.1-3, pag. 11 – 2009. Dini D., Malavasi N., Masini C., Barbieri E., Scarabelli L., Dieci MV., Marra L., Pashaj E., Gon A., Piccinini L. - Treatment of clear cell renal cell carcinoma with everolimus after progression on Sunitinib. Roberto Sabbatini, Cristina Masini. RCC Case studies: Volume 1-issue 2- 2010 - GESTIONE DEGLI EVENTI AVVERSI DA EVEROLIMUS NEL CARCINOMA RENALE METASTATICO: una guida pratica. Cap 4: Stomatite. Cristina Masini, Roberto Sabbatini - Case 9039: Localised nodular synovitis mimicking melanoma metastasis on PET-CT. MRI correlations. EuroRAD, Section Muskuloskeletal System, 2011 Jan. 7. Rinaldi D, Caprara M, Flocchi F, Masini C, Torricelli P - The adjuvant therapy of high-risk, resected, kidney cancer: from past failures to the hope coming from molecularly targeted agents. European Journal of clinical & medical oncology. December 2012. Camillo Porta, Chiara Paglino, Cristina Masini, Roberto Sabbatini - La gestione pratica del paziente oncologico in trattamento con everolimus: il carcinoma renale metastatico. Manuale pratico. Cristina Masini Cap 1,2,7,8 - Presente e futuro di Sorafenib in Oncologia. BAY 43-9006: studi di fase I e II e randomized discontinuation trial. Roberto Sabbatini, Cinzia Ortega, Cristina Masini, Veronica Prati.
Pubblicazioni in esteso	<ul style="list-style-type: none"> - Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer: BMC Cancer 2010 Mar 10;10:90. Laura Cortesi, Cristina Masini, Claudia Cirilli, Veronica Medici, Isabella Marchi, Giovanna Cavazzini, Giuseppe Pasini, Daniela Turchetti, Massimo Federico - Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <u>BJU Int.</u> 2012 Feb 24. Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moschetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cinzia Ortega, Laura Cosmai, Cinzia Del Giovane and Pier Franco Conte - <u>Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.</u> Ann Oncol. 2012 Jan 12. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Berfolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Meiello E, Tonini G - Isolation, Characterization And Transduction Of Endometrial Decidual Tissue Multipotent Mesenchymal Stromal/Stem Cells From Menstrual Blood. Biomed Res Int. 2013;2013:901821. doi: 10.1155/2013/901821. Epub 2013 Mar 31. Filippo Rossignoli, Anna Caselli, Giulia Grisendi, Maria Serena Piccinno, Jorge S. Burns, Alba Murgia, Elena Veronesi, Pietro Loschi, Cristina Masini, Pierfranco Conte, Paolo Paolucci, Edwin M. Horwitz and Massimo Dominici - Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal from intolerance to a tyrosine kinase inhibitor. <u>Future Oncol.</u> 2013 Jun;9(6):831-43. doi: 10.2217/fon.13.58. Sabbatini R, Ortega C, Procopio G, Masini C, Galligioni E, Porta C

- Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. *Clin Genitourin Cancer*. 2013 Nov 15. pii: S1558-7673(13)00276-0. doi: 10.1016/j.clgc.2013.11.005. [Epub ahead of print]. De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, Fornarini G, Burattini L, Rosti G, Ferrari V, Moscetti L, Chiuri VE, Luzi Fedeli S, Amadori D, Basso U
- Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. *J Geriatr Oncol*. 2014 Jan 22. pii: S1879-4068(14)00005-8. doi: 10.1016/j.jgo.2014.01.001. [Epub ahead of print]. De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U
- Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. *J Urol*. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. Matteo Santoni, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Umberto Basso, Ugo De Giorgi, Sergio Bracarda, Mimma Rizzo, Cinzia Ortega, Francesco Massari, Roberto Iacovelli, Lisa Derosa, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Francesco Alzori, Maria Pagano, Sebastiano Buti, Rocco De Vivo, Alessandra Mosca, Marta Rossi, Chiara Pagliano, Elena Verzoni, Linda Carbone, Giovanni Muzzonigro, Massimo Falconi, Rodolfo Montironi, Luciano Burattini, Daniele Santini and Stefano Cascinu
- The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer. *Cell Adh Migr*. 2015 Jan 6:0. [Epub ahead of print] Catania C, Maur M, Berardi R, Rocca A, Di Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, de Braud F
- Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. *Oncology*. 2015 Jan 15. [Epub ahead of print]. Sternberg CN¹, Calabrò F, Bracarda S, Carteni G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capececci B, Porta
- Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. *Can Urol Assoc J*. 2015 Jul-Aug;9(7-8):263-7. doi: 10.5489/cuaj.2377. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G
- Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. *Future Oncol*. 2015;11(23):3159-66. doi: 10.2217/fon.15.256. Epub 2015 Nov 6. Guida A, Masini C, Milella M, Di Lorenzo G, Santoni M, Prati V, Porta C, Cosmai L, Donati, del Giovane, Mighali P, Sabbatini R.
- Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review. *Clin Genitourin Cancer*. 2016 Aug;14(4):277-83. doi: 10.1016/j.clgc.2016.01.010. Epub 2016 Jan 28. Review. Leonetti A, Bersanelli M, Castagneto B, Masini C, Di Meglio G, Pellegrino B, Buti S.
- First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. *Clin Genitourin Cancer*. 2016 Dec 29. pii: S1558-7673(16)30370-6. doi: 10.1016/j.clgc.2016.12.024. [Epub ahead of print]. Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O.
- Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. *Breast Cancer Res*. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1. Iotti V, Ravaoli S, Vacondio R, Coriani C, Caffari S, Schedoni R, Nitrosi A, Ragazzi M, Gasparini E, Masini C, Bisacni G, Falco G, Ferrari G, Braiglia L, Del Prato A, Malavolti J, Ginocchi V, Pattacini P.
- Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer*. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Carteni G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregoni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vermieri C, Santini D, Soraru M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E
- Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? *Clin Genitourin Cancer*. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7. Iacovelli R¹, De Giorgi U², Galli L³, Zucali P⁴, Nolè F⁵, Sabbatini R⁶, Fraccon AP⁷, Basso U⁸, Mosca A⁹, Alzori F¹⁰, Santini D¹¹, Facchini G¹², Fornarini G¹³, Pasini F⁷, Masini C¹⁴, Massari F¹⁵, Buti S¹⁶, Sava T¹⁷, Sacco C¹⁸, Ricotta R¹⁹, Sperduti J²⁰, Tortora G²¹, Porta C²².

- The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. *Anticancer Drugs*. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. [Iacovelli R¹, Cossu Rocca M², Galli L³, Sabbatini R⁴, De Giorgi U⁵, Santini D⁶, Facchini G⁷, Mosca A⁸, Atzori F⁹, Zucali P¹⁰, Fornarini G¹¹, Massari F¹², Buti S¹³, Ricotta R¹⁴, Masini C¹⁵, Toscani F¹⁵, Biasco E³, Guida A⁴, Loli C⁵, De Lisi D⁶, Rossetti S⁷, Terrone C⁸, Scartozzi M⁹, Miggiano C¹⁰, Pastorino A¹¹, Bersanelli M¹², Carlo-Stella G¹⁴, Pinto C¹⁵, Nobili E¹², Nolè F², Tortora G¹, Porta C¹⁵](#).
- Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. *PLoS One*. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. eCollection 2018. [Vitale MG¹, Scaqlianni S², Galli L³, Pignata S⁴, Lo Re G⁵, Berruti A⁶, Defferran C⁷, Spada M⁸, Masini C⁹, Santini D¹⁰, Ciuffreda L¹¹, Ruggeri EM¹², Bengala C¹³, Livi L¹⁴, Fagnani D¹⁵, Bonetti A¹⁶, Giustini L¹⁷, Hamzaï A¹⁸, Procopio G¹⁹, Caserta C²⁰, Sabbatini R¹](#).
- Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. *Anticancer Res*. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticancer.12807. [Sbrana A¹, Biasco E², Paolieri F³, Palesandro E⁴, Caserta C⁵, Iacovelli R⁵, Detti B⁷, Santini D⁸, Mosca A⁹, Morelli F¹⁰, Fornarini G¹¹, De Giorgi U¹², Masini C¹³, Galli L³](#).
- Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. *Masini C¹, Vitale MG², Meruzzo M³, Procopio G⁴, de Giorgi U⁵, Buti S⁶, Rossetti S⁷, Iacovelli R⁸, Atzori F⁹, Cosmai L¹⁰, Vignani F¹¹, Prati G¹², Scaqlianni S¹³, Guida A¹⁴, Berselli A², Pinto C². Clin Genitourin Cancer*. 2018 Oct 10. pii: S1558-7673(18)30096-X. doi: 10.1016/j.clgc.2018.10.001. [Epub ahead of print]
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. *Sternberg CN¹, Loriot Y², James N³, Choy E⁴, Castellano D⁵, Lopez-Rios F⁶, Banna GL⁷, De Giorgi U⁸, Masini C⁹, Bamias A¹⁰, Garcia Del Muro X¹¹, Duran J¹², Powles T¹³, Gamulin M¹⁴, Zengerling F¹⁵, Geczi L¹⁶, Gedye C¹⁷, de Ducla S¹⁸, Fear S¹⁸, Merseburger AS¹⁹. Eur Urol*. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.
- The effect of a treatment delay on outcome in metastatic renal cell carcinoma. [Iacovelli R¹, Galli L², De Giorgi U³, Porta C⁴, Nolè F⁵, Zucali P⁶, Sabbatini R⁷, Mosca A⁸, Atzori F⁹, Santini D¹⁰, Facchini G¹¹, Fornarini G¹², Buti S¹³, Massari F¹⁴, Masini C¹⁵, Ricotta R¹⁶, Biasco E², Loli C³, Gri N⁴, Verri E⁵, Miggiano C⁶, Vitale MG⁷, Tortora G¹⁷. Urol Oncol. 2019 Aug;37\(8\):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.](#)
- Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). [Vitale MG¹, Bracarda S², Cosmai L³, Crocetti E⁴, Di Lorenzo G⁵, Lapini A⁶, Mandressi A⁷, Martorana G⁸, Masini C⁹, Montironi R¹⁰, Ortega C¹¹, Passalacqua R¹², Porta C¹³, Procopio G¹⁴, Sepe P¹⁴, Romano L¹⁵, Pappagallo GL¹⁶, Confi G¹⁷, Guida M¹⁸, Martignoni G^{19,20}, Nolè F²¹, Pignata S²², Gori S²³, Carteni G²⁴. Tumori. 2019 Jul;105\(4_suppl\):3-12. doi: 10.1177/0300891619853392](#).

Abstracts

- Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. Filippo de Braud, Chiara Catania, Rossana Berardi, Chiara Pierantoni, Stefano Cascinu, Michela Maur, [Cristina Masini](#), Pier Franco Conte, Leonardo Giannoni, Annalisa Tasciotti, Valeria Lovato, Dario Neri, Hans D. Menssen. ASCO 2011: Supplement to Journal of Clinical Oncology 2011
- Safety of Everolimus in patients with metastatic renal cell carcinoma previously treated with VEGF/VEGFR inhibitors. [Sabbatini R., Masini C., Ferrari A., Del Giovane C., Conte P.F.](#) Supplemento Tumori XII Congresso Nazionale 2010
- Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer. Ugo De Giorgi, Karim Rihawi, Giovanni Lo Re, Teodoro Sava, [Cristina Masini](#), Michele Aieta, Andrea Camerini, Giuseppe Fornarini, Luciano Burattini, Fabio De Vincenzo, Giovanni Rosti, Vittorio D. Ferrari, Luca Moschetti, Vincenzo Emanuele Chiuri, Stefano Luzi Fedeli, Emanuela Scarpi, Umberto Basso. ASCO GU 2012. J Clin Oncol 30, 2012 (suppl 5; abstr 411)
- Treatment of hemodialyzed patients with metastatic renal cell carcinoma with mTOR inhibitors. [Cristina Masini](#), Alessandra Felici, Giuseppe di Lorenzo, Azzurra Onofri, Veronica Prati, Pasquale Mighali, PierFranco Conte, Roberto Sabbatini. Abstract n. 42. Anticancer Research, International Journal of Cancer Research and Treatment. Volume 32, Number 5, pp1843-1966, May 2012
- Progression free survival (PFS) and Overall survival (OS) in patients receiving 3 targeted therapies (TTS) for metastatic renal cell carcinoma (mRCC). [R.Iacovelli, M.Santoni, G.Di Lorenzo, L.Cerbone, M.Aglietta, C. Masini, M.O.Giganfi, C. Messina, C.N. Sternberg, G. Procopio.](#) Abstract 818P, ESMO 2012

- Treatment of patients with metastatic kidney cancer during haemodialysis with mTOR inhibitors. C.Masini, M.Milella, A.Onofri, M.Santoni, V.Prali, M.Nicodemo, P.F. Conte, R.Sabbatini. Abstract 879, ESMO 2012
- Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC). Elena Verzoni, Roberto Iacovelli, Mimma Rizzo, Alessandra Felici, Stefano Cascinu, Giuseppe Di Lorenzo, Linda Cerbone, Cinzia Ortega, Cristina Masini, Maria Olga Giganti, Vito Lorusso, Caterina Messina, Francesco Atzori, Fabio De Vincenzo, Cosimo Sacco, Francesco Boccardo, Francesco Valduga, Francesco Massari, Renato Tassi, Giuseppe Procopio. ASCO GU 2013, J Clin Oncol 31, 2013 (suppl 6; abstr 431)
- Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC). Stephane Oudard, Bernard J. Escudier, John A. Thompson, Viktor Grünwald, Cristina Masini, Sergio Bracarda, Ashok Panneerselvam, Sven Gogov, David Chen, Robert John Motzer. ASCO GU 2013, J Clin Oncol 31, 2013 (suppl 6; abstr 352)
- Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience. Giuseppe Procopio, Lisa Derosa, Angela Gernone, Franco Morelli, Teodoro Sava, Vittorina Zagonel, Ugo De Giorgi, Vittorio D. Ferrari, Cristina Masini, Donatello Gasparro, Alessandra Felici, Rossana Berardi, Nicola Calvani, Giovanni Lo Re, Helga Lipari, Maria Pia Brizzi, Michele Sisani, Camillo Porta, Enzo Galligioni, Antonio Silverio Contu, RESET Study Group. ASCO GU 2013, J Clin Oncol 31, 2013 (suppl 6; abstr 415)
- Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Ugo De Giorgi, Karim Rihawi, Michele Aieta, Giovanni Lo Re, Teodoro Sava, Cristina Masini, Valentina Baldazzi, Fabio De Vincenzo, Andrea Camerini, Giuseppe Fomarin, Luciano Burattini, Giovanni Rosti, Luca I. Moschetti, Vincenzo Emanuele Chiuri, Stefano Luzi Fedeli, Vittorio D. Ferrari, Dino Amadori, Umberto Basso. ASCO 2013, J Clin Oncol 31, 2013 (suppl 6; abstr 15615)
- The prognostic role of HPV status in oropharyngeal cancer: a single institution experience. Spallanzani A., Marra L., Gelsomino F., Madrigali S., Bertolini F., Depenni R., Cantile F., Fontana A., Masini C., D'Angelo E., Ghidini A., Parmiggiani M., Ponti G., Luppi G. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- Irinotecan -based regimen as second-line chemotherapy in patients with metastatic neuroendocrine carcinomas: experience in nine cases. Gelsomino F., Fontana A., Spallanzani A., Bertolini F., Zironi S., Depenni R., Masini C., Madrigali S., Luppi G. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- "Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final Italian results". Cora N. Sternberg, Sergio Bracarda, Giacomo Carteni, Giovanni Lo Re, Enzo M. Ruggeri, Cristina Masini, Kolette Fly, Ke Zhang, Subramanian Hariharan, Camillo Porta. ESMO-ECCO Congress 2013, Poster discussion 2707. EJC volume 49, supplement 2, september 2013
- Safety of targeted therapies (TTS) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD). Masini C., Porta C., Milella M., Procopio G., Di Lorenzo G., Santoni M., Buti S., Iacovelli R., Invernizzi R., Moschetti L., Aste M.G., Pagano M., Grosso F., Manenti A.L., Ortega C., Cosmai L., Nicodemo M., Donati D., Del Giovane C., Sabbatini R. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- Clinico-pathological features and prognosis of patients with late-relapsing (>5 years) renal cell carcinoma after curative surgery: results from later study. Burattini L., Santoni M., Porta C., Procopio G., Cerbone L., Maruzzo M., De Giorgi U., Rizzo M., Ballatore V., Massari F., Iacovelli R., Masini C., Milella M., Di Lorenzo G., Atzori F., Pagano M., De Vivo R., Berardi R., Santini D., Cascinu S. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- Safety and efficacy of Everolimus given at 10 mg in advanced renal cell carcinoma (RCC) patients with stage III to V chronic kidney disease (CKD). Porta C., Cornacchia F., Masini C., Sabbatini R., Ganini C., Cosmai L. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- PSA decrease during enzalutamide treatment in castration-resistant prostate cancer (CRPC) patients: results from name patient program (NPP) in 4 Italian institutions. Sabbatini R., Iacovelli R., Derosa L., Procopio G., Alesini D., Cortesi E., Modica D., Galli L., Clò V., Gelsomino F., Cantile F., Toss A., Dominici M., Mighali P., Del Giovane C., Masini C. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- Pooled analysis of efficacy of second-to-third line chemotherapy nationwide for patients with advanced transitional-cell carcinoma (TCC). Atzori F., Marongiu M., Santoni M., Derosa L., Di Lorenzo G., Masini C., Iacovelli R., Massari F., Burattini L., Raggi D., Federico P., Biasco E., Notari F., Sabbatini R., Ionta M.T., Necchi A. Supplemento Tumori XV Congresso Nazionale AIOM 2013
- Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery? Matteo Santoni, Alessandro Conti, Camillo Porta, Linda Cerbone, Giuseppe Procopio, Umberto Basso, Ugo De Giorgi, Mimma Rizzo, Cinzia Ortega, Francesco Massari, Roberto Iacovelli, Cristina Masini, Michele Milella, Giuseppe di Lorenzo, Maria Pagano, Sebastiano Buti, Massimo Falconi, Luciano Burattini, Daniele Santini, Stefano Cascinu. J Clin Oncol 32, 2014 (suppl: abstr e15563)

- Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. Domenica Lorusso, Gabriella Ferrandina, Sandro Pignata, Roberto Sorio, Antonella Pietragalla, Anna Maria Mosconi, Carmela Pisano, Giorgia Mangili, Fabio Martinelli, Cristina Masini, Grazia Artioli, Filomena Narducci, Marilena Di Napoli, Francesco Raspagliesi, Giovanni Scambia. J Clin Oncol 32:5s, 2014 (suppl; abstr 5530^A)
- OPTIMIZATION OF NOVEL METABOLOMIC APPROACH FOR DETECTION OF NEW POTENTIAL BIOMARKERS FOR PROSTATE CANCER. Adriana Albini, Daniela Farioli, Katiuscia Dallaglio, Martina Chiappelli, Cristina Masini, Matteo Conti, Antonino Bruno, Paolo Consonni, Douglas M. Noonan. Supplemento Tumori XVI Congresso Nazionale AIOM 2014
- Cristina Masini, Claudia Omarini, Maria Pagano, Licia Baldi, Giuseppe Prati, Pasquale Mighali, Erika Gervasi, Ermanno Rondini, Viola De Luca, Cinzia del Giovane, Corrado Boni, Adriana Albini, Laura Scaltriti, Roberto Sabbatini. Clinical impact of new drugs in metastatic castration-resistant prostate cancer (mCRPC): results from a real world experience. Supplemento Tumori XVI Congresso Nazionale AIOM 2014
- Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment. Cristina Masini, Alessandra Bisagni, Giuseppe Falco, Cristina Bassano, Licia Baldi, Giancarlo Bisagni, Gabriella Moretti, Adriana Albini, Guglielmo Ferrari, Corrado Boni, Giorgio Gardini. J Clin Oncol 33, 2015 (suppl; abstr e11605)
- HER2 amplification level and tumor-infiltrating lymphocytes (TIL) in breast cancer patients treated with neoadjuvant Trastuzumab. Masini C, Ragazzi M, Bisagni A, Dallaglio K, Falco G, Bassano C, Ferrari G, Gardini G, Bologna A, Moretti G, Pinto C, Bisagni G. J Clin Oncol 34, 2016 (suppl; abstr 596)
- First-line Pazopanib in Non-clear cell Renal carcinoma: the Italian retrospective multicenter PANORAMA study. M. Bersanelli, F. Maines, G. Facchini, F. Gelsomino, F. Zustowich, M. Santoni, E. Verri, U. De Giorgi, C. Masini, F. Morelli, M.G. Vitale, T. Sava, G. Prati, C. Liboni, A.P. Fracon, G. Fornarini, M. Maruzzo, F. Leonardi, O. Caffo, S. Buti. Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
- The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study. Maria Giuseppe Vitale, Cristina Masini, Giuseppe Procopio, Ugo De Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Claudia Mucciarini, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Berselli, Carmine Pinto. J Clin Oncol 35, 2017 (suppl; abstr e16063)
- Correlation between clinical-disease characteristics and compliance to immunotherapy in metastatic solid tumors in a real world setting. First results of Italian CORE-IMMUNO Study. C. Masini¹, A. Berselli¹, M. Banzì¹, C. Bonelli¹, A. Romagnani¹, M. Pagano¹, A. Damato¹, G. Prati², E. Gasparini³, G. Moretti¹, I.T. Lorenzetti¹, F. Zaneli¹, F. Iachetta¹, C. Pinto¹. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288
- Correlation between clinical-disease characteristics and compliance to immunotherapy in metastatic solid tumors in a real world setting. First results of Italian CORE-IMMUNO Study. C. Masini¹, A. Berselli¹, M. Banzì¹, C. Bonelli¹, A. Romagnani¹, M. Pagano¹, A. Damato¹, G. Prati², E. Gasparini³, G. Moretti¹, I.T. Lorenzetti¹, F. Zaneli¹, F. Iachetta¹, C. Pinto¹. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288
- First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study. C. Masini¹, P. Ciammella², G. Timon², R. Gnoni¹, U.F.F. De Giorgi³, S.R. Bellia⁴, S. Buti⁵, F. Salaroli⁶, M. Milella⁷, R. Mazzarotto⁸, C. Mucciarini⁹, M.G. Vitale¹⁰, A. Bruni¹¹, G. Procopio¹², S. Kinspergher¹³, F. Nole¹⁴, F. Morelli¹⁵, G. Pappagallo¹⁶, C. Buttigliero¹⁷, C. Pinto¹⁸. Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Dal 2010 ad oggi relatrice a più di 50 congressi regionali/macro-regionali o Nazionali.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

Carlo Messina, M.D.
CURRICULUM VITAE



PERSONAL DETAILS:

First Name	Carlo
Surname	Messina
Specialty	Medical Oncologist
Nationality	Italian
Gender	Male
Date of birth	
Current Address	
Permanent Address	
Mobile	
Email	
Work Address	Oncology Unit, A.R.N.A.S Civico

EDUCATION, MEDICAL AND ACADEMIC DEGREES:

Diploma/Degree	Subject School	Year of Graduation
Medical Post-degree fellowship	'School of Medical Oncology', National Cancer Research Institute; Department of Medical Oncology (Director: Prof. Francesco Boccardo). University of Genoa. Italy.	August 2013 - August

		2018
Professional registration	National board for Clinical practice	February 2013
MD degree	Medical and Surgical degree. 110/110 cum laude. School of Medicine: Policlinico universitario Paolo Giaccone, Palermo Italy. Final dissertation: " <i>Biological features, prognostic factors and outcome in 114 patients with GISTs, a single institution experience</i> "	July 2012
Secondary School	High School Diploma (100/100), Liceo Classico G.Meli, Palermo, Italy	July 2006

LANGUAGES:

Italian	Native
English	Fluent. English certificate: - IELTS: level B2 (February 2018) - Trinity: 9/12 level B2 (May 2005)

COMPUTER SKILLS:

Operating Systems	Windows, Apple Macintosh
Software applications	Word, Excel, Outlook, Explorer, Power Point, Medical software for chemotherapy prescription

PROFESSIONAL QUALIFICATIONS AND EXPERIENCE

February 2021: consultant in the Oncology Unit of A.R.N.A.S Civico Hospital, Palermo (Italy), under the direction of L. Blasi

November-December 2019: Scholarship at British Columbia Cancer Agency (BCCA) under the direction of Professor C. Koolmansbergher.

Since October 2018: consultant in the Oncology Unit of S. Chiara Hospital, Trento (Italy) under the direction of O. Caffo M.D.

October 2017- July 2018: fellow at The Royal Marsden Hospital, Prostate Cancer Targeted Therapy Group Unit, under the direction of Prof. Johann Sebastian De Bono.

Academic Year 2014: Post degree fellowship ‘School of Internal Medicine’ San Martino Hospital; Department of Internal Medicine (Director: G. Murialdo), Genoa University.

Academic Year 2011-2013: Experience in Oncology at GIST, NETs, Sarcoma Unit, Department of Clinical Oncology, University of Palermo, Italy, (Director: Prof. A. Russo) as medical student, being actively part of several clinical trials and research projects management, especially in the field of rare tumors, which was the subject of my experimental degree thesis.

August 2011: Research Exchange, with the experimental project titled: “Molecular Epidemiology of Hepatitis B, C, E”, Department of Microbiology and Tropical disease, University of Surabaya, Indonesia.

August 2010: Professional Exchange Program at Department of “Internal Medicine” Faculty Motol Hospital, University Karlova V, Prague, Czech Republic,

August 2009: Professional Exchange Program at Department of “Internal Medicine”, Al Makassed Hospital, Jerusalem.

MERIT AWARD

- La Clessidra/AIOM foundation award for the scholarship at British Columbia University under the direction of Professor Koolmannsberger.

AREAS OF SCIENTIFIC INTERESTS:

- Genito-Urinary Cancers
- Gynecological Cancers
- Gastro-intestinal cancers
- Breast Cancer

MEMBERSHIP OF SCIENTIFIC SOCIETIES:

- European Organization for Research and Treatment of Cancer (EORTC)- since February 2017
- American Society of Clinical Oncology (ASCO)- since August 2013
- European Society for Medical Oncology (ESMO)- since August 2013
- Associazione Italiana di Oncologia Medica (AIOM)- since August 2013

SPEAKER AT THE FOLLOWING MEETING

- 23/10/21 AIOM Italian Congress, Rome. Inxtant: Evidence of new Androgen receptor targeting agent for metastatic hormone sensitive prostate cancer.
- Multidisciplinary approach for the treatment of mRCC: which best TKI in first line ?
- Palermo 27/09/21. First Sicilian GOM Ovary Cancer SiGoOC-1
- Palermo 5/03/21 AIOM regional meeting. Treatment strategy of locally advanced pancreatic cancer.
- Trento 16-11-20. Treatment of mRCC.

- Pollina 16-17/10/20. Percorsi diagnostico terapeutici simulati, sliding doors: trattamento del carcinoma metastatico avanzato.
- 2-10-20 Tutti x uno, Padova. Sequencing strategies in mCRPC
- 21-22/01/2020 Pro-state of the art, European conference SIURO: management of metastatic castration resistant prostate cancer.
- 6-7/12/2019 Negrar: the multidisciplinary team for the treatment of prostate cancer
- 12-10-2019 Cefalu': focus on urological and upper GI neoplasms
- 06-07-2019 Perugia: treatment of metastatic castration resistant prostate cancer: from M0 disease towards mCRPC. AIOM giovani 2019.
- 23-06-2017 Genoa: May Adjuvant or Neo-adjuvant therapy play a role for the treatment of localized RCC? ACC Med Symposium.
- 2016 Valencia: oral presentation of a clinical case at ESMO preceptorship on the management of CRC.
- 2014 Genoa: X regional congress, AIOM Liguria "molecular predictive factor of response to targeted therapies"

PARTECIPATION AT NATIONAL AND INTERNATIONAL MEETING

- 2021(GENOA) GRANDANGOLO IN ONCOLOGIA
- 2021 ESMO VIRTUAL MEETING
- 2021 ASCO VIRTUAL MEETING
- 2020 AIOM VIRTUAL MEETING
- 2020 ESMO VIRTUAL MEETING
- 2020 ASCO VIRTUAL MEETING
- 2020 (SAN FRANCISCO) ASCO GU
- 2019 (ROME) AIOM CONGRESS
- 2019 (BARCELONA) ESMO CONGRESS
- 2019 (BARCELONA) ESMO PRECEPTORSHIP ON GASTRIC CANCER
- 2019 (WIEN) ST. GALLEN BREAST CANCER SYMPOSIUM
- 2018(MUNICH) ESMO CONGRESS
- 2018(ROME) AIOM CONGRESS
- 2018 (BARCELONA) ESMO SYMPOSIUM ON SIGNALLING PATHWAY
- 2017 (MADRID) ESMO CONGRESS
- 2017 (ROME) AIOM CONGRESS
- 2016 (COPENAGHEN) ESMO CONGRESS
- 2015 (VIENNA) ECCO CONGRESS
- 2015(GENOA) GRANDANGOLO IN ONCOLOGIA
- 2015 (ROME) AIOM CONGRESS
- 2014 (GENOA) GRANDANGOLO IN ONCOLOGIA
- 2014 (ROME) AIOM CONGRESS
- 2013 (MILAN) AIOM CONGRES

PUBLICATIONS:

- Vernuccio F, **Messina C**, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. *Diagnostics (Basel)*. 2021 Nov 22;11(11):2166
- Salati M, Rizzo A, Merz V, **Messina C**, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. *Expert Rev Gastroenterol Hepatol*. 2021 Dec 21:1-7.
- Caffo O, Messina M, Vecchia A, Kinspergher S, Maines F, **Messina C**. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review. *Crit Rev Oncol Hematol*. 2021 Nov;167:103491.
- De Giorgi U, Buti S, Santini D, Casadei C, Sorarù M, **Messina C**, Mucciarini C, Di Lorenzo G, Roviello G, Buttigliero C, Stellato M, Sepe P, Claps M, Guadalupi V, Ottini A, Pignata S, De Braud FG, Verzoni E, Procopio G. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). *Expert Rev Anticancer Ther*. 2021 Nov 5
- Cattrini C, **Messina C**, Airoidi C, Buti S, Roviello G, Mennitto A, Caffo O, Gennari A, Bersanelli M. Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. *Ther Adv Urol*. 2021 Oct 29;13:17562872211053189.
- Tovoli F, Dadduzio V, De Lorenzo S, Rimassa L, Masi G, Iavarone M, Marra F, Garajova I, Brizzi MP, Daniele B, Trevisani F, **Messina C**, Di Clemente F, Pini S, Cabibbo G, Granito A, Rizzato MD, Zagonel V, Brandi G, Pressiani T, Federico P, Vivaldi C, Bergna I, Campani C, Piscaglia F. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. *Liver Cancer*. 2021 Jul;10(4):370-379.
- Roviello G, Buti S, Cattrini C, Mennitto A, **Messina C**, Airoidi C, Vannini G, Bersanelli M. Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? *Ther Adv Urol*. 2021 Jul 8;13:17562872211029784.
- Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Tomasello L, Fratino L, Baldessari C, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Stellato M, Atzori F, Pignata S, **Messina C**, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Pierantoni F, Casadei C, Bersanelli M, Chiellino S, Paolieri F, Perrino M, Brunelli M, Iacovelli R, Porta C, Buti S, Fornarini G. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). *Ther Adv Med Oncol*. 2021 May 18;13:17588359211019642.
- **Messina C**, Salati M, Messina M, Cattrini C, Merz V, Caffo O. Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials. *Eur J Clin Invest*. 2020 Dec 31:e13483

- Merz V, Ferro A, Piras EM, Zanutto A, Caffo O, **Messina C**. Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience. *JCO Oncol Pract*. 2021 Jan;17(1):e44-e52.
- Barranco Rosario, **Messina Carlo**, Bonsignore Alessandro, Cattrini Carlo, Ventura Francesco. Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty? *Frontiers in Public Health*. 2020 Dec 18
- Nappi L, Ottaviano M, Rescigno P, **Messina C**, Palmieri G. In response to: Metastatic mediastinal germ-cell tumor and concurrent COVID-19: when chemotherapy is not deferrable. *Oncologist*. 2020 Dec 21.
- Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, **Messina C**, Rediti M, Russo A, Bazan V, Iovanna JL. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. *Oncoimmunology*. 2020 Oct 27;9(1):1832348
- Caffo O, Maines F, Kinspergher S, Veccia A, **Messina C**. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today? *Expert Rev Anticancer Ther*. 2020 Nov 27.
- Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, **Messina C**, Rediti M, Russo A, Bazan V, Iovanna JL. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. *Oncoimmunology*. 2020 Oct 27;9(1):1832348.
- Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, **Messina C**, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros MB, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Characterizing CDK12-Mutated Prostate Cancers. *Clin Cancer Res*. 2020 Sep 28: clincanres.2371.2020.
- Caffo O, Gasparro D, Di Lorenzo G, Volta AD, Guglielmini P, Zucali P, Bortolus R, Cavo A, Ceresoli G, Chiari R, Fornarini G, Fratino L, Iaculli A, Maruzzo M, Masini C, Morelli F, Mucciarini C, Procopio G, Sabbatini R, Verri E, Kinspergher S, Maines F, **Messina C**, Veccia A, Donini M. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. *Eur J Cancer*. 2020 Oct 19;140:140-146.
- Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, **Messina C**, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *J Immunother Cancer*. 2020 Oct;8(2):e001154.
- Cattrini C, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, **Messina C**, Castro E, Olmos D, Boccardo F. Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. *Cancers (Basel)*. 2020 Oct 3;12(10):E2855.

- **Messina C**, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. *J Oncol*. 2020 Sep 7;2020:4986365.
- Lucia Nappi, Margaret Ottaviano, Pasquale Rescigno, Marianna Tortora Giuseppe Banna,⁷ Giulia Baciarello, Umberto Basso, Christina Canil, Alessia Cavo, Maria Cossu Rocca, Piotr Czaykowski, Ugo De Giorgi, Xavier Garcia del Muro, Marilena Di Napoli, Giuseppe Fornarini, Jourik A. Gietema, Daniel Heng, Sebastien Hotte, Christian Kollmannsberger, Marco Maruzzo, **Carlo Messina**, Franco Morelli, Sasja Mulder, Craig Nichols, Franco Nolè, Christoph Oing, Teodoro Sava, Simona Secondino, Giuseppe Simone, Denis Soulieres, Bruno Vincenzi, Paolo Andrea Zucali and Giovannella Palmieri,⁸ on behalf of Italian Germ Cell Cancer Group (IGG), the ERN-EURACAN G3 Domain and the Genitourinary Medical Oncology Canadian (GUMOC) group. Management of testicular germ cell tumors during the outbreak of novel coronavirus disease-19 pandemic: a survey from international expertise centers. Accepted in the journal the *Oncologist*, July 2020
- Sinagra E, Luppino I, Messina M, Stasi E, Utzeri E, **Messina C**, Belletrutti P, Fabbri C, Anderloni A. Endoscopic approach to early gastric cancer in older adults. *J Geriatr Oncol*. 2020 May 26:S1879-4068(20)30208-3.
- Merz V, Cavaliere A, **Messina C**, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, Melisi D. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. *Cancers (Basel)*. 2020 Apr 30;12(5):1131.
- **Messina C**, Messina M, Cattrini C. From astrology to prostate cancer: what is the role of subgroup analyses? *Ann Oncol*. 2020 Mar;31(3):437-438.
- Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, **Messina C**, Sumanasuriya S, Bianchini D, Barrero M, Petremolo A, Zafeiriou Z, Fontes MS, Perez-Lopez R, Tunariu N, Fulton BA, Jones R, McGovern UB, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Genomics of lethal prostate cancer at diagnosis and castration-resistance. *J Clin Invest*. 2019 Dec 24.
- Salati M, Baldessari C, Bonetti LR, **Messina C**, Merz V, Cerbelli B, Botticelli A. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. *Crit Rev Oncol Hematol*. 2019 Dec;144:102826.
- **Messina C**, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis. *Critical Review in Oncol Hematol*. 2019 Nov; 143:124-129.
- Caffo O, Maines F, Kinspergher S, Veccia A, **Messina C**. Sequencing strategies in the new treatment landscape of prostate cancer. *Future Oncol*. 2019 Sep;15(25):2967-2982.
- Vallome G, Cattrini C, **Messina C**, Cerbone L, Boccardo F, Zanardi E. Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience. *Anticancer Drugs*. 2019 Jul 22.
- Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, **Messina C**, Zanardi E, Boccardo F. Prognostic variables in patients with non-metastatic small-cell neuroendocrine carcinoma of the bladder: a population-based study. *Clinical Genitourinary cancer*. 2019 Mar 28.
- Badalamenti G, Incorvaia L, **Messina C**, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. *Support Care Cancer*. 2019 Feb 14.
- **Messina C**, Cattrini C, Buzzatti G, Cerbone L, Zanardi E, Messina M, Boccardo F. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. *Breast Cancer Res Treat*. 2018 Nov;172(1):9-21.

- Rediti M, **Messina C.** Towards treatment personalization in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy. *Breast Cancer Res Treat.* 2018 Jul 12.
- Badalamenti G, **Messina C.** De Luca I, Musso E, Casarin A, Incorvaia L. Soft Tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. *La Radiologia Medica.* 2018 March 29; <https://doi.org/10.1007/s11547-018-0883-6>
- Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, **Messina C.** Boccardo F. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. *Ther Adv Med Oncol.* 2018 Jan 9; 10:1758834017745819.
- Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, Di Meglio A, Fabbroni C, Latocca MM, Rizzo F, **Messina C.** Rubagotti A, Barboro P, Boccardo F. Targeting androgen-independent pathways: new chances for patients with prostate cancer? *Crit Rev Oncol Hematol.* 2017 Oct; 118:42-53.
- **Messina C.** Messina M, Zanardi E. Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer. *Ann Oncol.* 2017 Dec 1;28(12):3099-3100.
- **Messina C.** Messina M, Boccardo F. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! *Eur Urol.* 2017 Aug 8.
- **Messina C.** Zanardi E, Boccardo F. May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials. *Anticancer Agents Med Chem.* 2017 Feb 13.
- **Messina C.** Buzzatti G, Dellepiane C, Cavo A, Tolomeo F, Cattrini C, Boccardo F. Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives. *Anticancer Drugs.* 2016 Nov;27(10):917-43.
- Cattrini C, Dellepiane C, Cavo A, Buzzatti G, Tolomeo F, **Messina C.** Boccardo F. Immunotherapy for genitourinary cancer: state of the art and new perspectives. *Anticancer Drugs.* 2016 August; 27 (7): 585-99.
- **Messina C.** Messina M. Advanced pure seminoma in a young HIV-positive patient; a case report and review of literature. *Reproductive system and Sexual disorders: Current research.* 2016, June; 5:2.
- **Messina C.** Zanardi E, Dellepiane C, Tomasello L, Colecchia M, Ravetti GL, Boccardo F, Spina B. A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature. *Clin Genitourin Cancer.* 2016 Feb; 14 (1): e139-42.
- **Messina C.** Dellepiane C, Caroti C, Sarocchi F, Ravetti GL, Boccardo F, Spina B. A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated with Capecitabine-Based Chemotherapy and Review of Literature. *Clin Genitourin Cancer.* 2015 Oct;13(5):e365-8.
- **Messina C.** Di Meglio A, Nuzzo PV, Boccardo F, Ricci F. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report. *Tumori.* 2015 May-Jun; 101(3):e79-81.

POSTERS PRESENTATION AND ABSTRACTS

- Merz V, Ferro A, Piras E.M., Zanutto A, Caffo O, **Messina C.** Electronic medical record-assisted phone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience. Accepted as Poster at ESMO 2020.
- Caffo O, Aieta M, Macerelli M, Mucciarini C, Nicodemo M, De Giorgi U, Sartori D, Fratino L, Iacovelli S, Rossetti S, Scapoli D, Morelli F, Carrozza F, Nolè F, Zagonel Vittorina, **Messina C.**, Gasparro D. Enzalutamide re-challenge as second line in metastatic castration resistant prostate cancer patients treated with first line enzalutamide-docetaxel: preliminary results of post-progression analysis of Cheiron trial. Accepted as poster at ASCO GU 2020.
- Ferro A, Caldara A, Grego E, **Messina C** et al. Impact of pathologic complete response and biological features of residual tumor on prognosis after neoadjuvant chemotherapy in various invasive breast cancer subtypes. Poster accepted at St. Antonio Breast Cancer Symposium 2019.
- **Messina C.**, Merz V, Frisinghelli M, Trentin C, Grego E, Salati M, Messina M, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: a systematic review and meta-analysis of randomized trials. Poster accepted at AIOM annual meeting 2019.
- Barrero M, Mattia Rediti, Mateus Crespo, David Dolling, Pasquale Rescigno, **Carlo Messina**, Robert Chandler, Diletta Bianchini, Antonella Petremolo, Ruth Riisnaes, Ana Ferreira, Daniel Nava Rodrigues, Claudia Bertan, Adam Sharp, Semini Sumanasuriya, Alec Paschalis, Nina Tunariu, Joaquin Mateo, Suzanne Carreira, Johann S. De Bono. Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer. Poster accepted at ASCO Annual Meeting 2018.
- P. Rescigno, M. Rediti, D. Dolling, D.N. Rodrigues¹, D Bianchini, R. Riisnaes, **C. Messina**, M. Barrero, A. Petremolo, A. Sharp, S. Sumanasuriya, G. Seed, I. Figueiredo, S. Miranda, J. Goodall, J. Mateo, R. Chandler, W. Yuan, S. Carreira, J.S. de Bono. PI3K/AKT pathway deleterious mutations in lethal prostate cancer. Poster accepted at ESMO 2018.
- **Messina C.**, Cattrini C, Buzzatti G, Cerbone L, Messina M, Boccardo F, Zanardi E. CDK inhibitors in advanced HR+ Her 2- breast cancer: a systematic review and meta-analysis of randomized trials. Abstract accepted at ASCO Annual Meeting 2018.
- Carlo Cattrini, Luigi Cerbone, Alessandra Rubagotti, Linda Zinoli, Maria Maddalena Latocca, Giulia Buzzatti, Giacomo Vallome, Fabio Rizzo, Alessia Cavo, Kristi Beshiri, Davide Soldato, **Carlo Messina**, Elisa Zanardi, Francesco Boccardo. Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study. Abstract accepted at ASCO Annual Meeting 2018.
- Cattrini C, Rubagotti A, Nuzzo P.V., Zinoli L., Salvi S., Boccardo S., Spina B., Toncini C., Perachino M., Cavo A, Cerbone L, **Messina C.**, Di Meglio A., Zanardi E, Boccardo F. Over-expression of periostin in tumour biopsies is associated with aggressive prostate cancer. Eur Urol Suppl 2017; 16 (10); w2735
- **Messina C.**, Messina M. Efficacy and safety of Sunitinib and Everolimus as front-line treatment for nonclear cell RCC: a pooled-analysis from randomized trials. Journal of Clinical Oncology 2017 35:15_suppl, e16069-e16069
- Bruzzzone M, Dellepiane C, Bo E, Cavo A, Giannelli F, Centurioni MG, Cosso M, Alessandri F, Vellone VG, Sirito R, Zanardi E, Buzzatti G, **Messina C.**, Cattrini C, Gustavino C, Boccardo F. Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study. J Clin Oncol 34, 2016 (suppl; abstr 5529).
- **Messina C.**, Marco M, Provenzano S, Badalamenti G Biological features, prognostic factors and outcome in 114 patients with GISTs, a single institution experience. J Clin Oncol 33, 2015 (suppl; abstr e21507).

- **Messina C**, Gristina L, Badalamenti G, Provenzano S, Maltese G, Messina M. Biological features, prognostic factors and outcome in 114 patients with GISTs, a single institution experience. *Annals of Oncology* 2013.
- **Messina C**, Badalamenti G, Provenzano S, Messina M, Gristina L. Biological features, prognostic factors and outcome in 114 patients with GISTs, a single institution experience. *Tumori* 2013.
- Ina Macaione, S. Provenzano, A. Mastrosimone, G. Maltese, G. Badalamenti, A. Russo, E. Fiorentino, F. Patti, V. Vanella, **C. Messina**, G. Pantuso: A mono institutional experience in Gastro-Intestinal Stromal Tumours of the stomach: analysis of 58 cases. General poster session, 10 th International Gastric Cancer Congress, Verona (2012), Italy.
- Messina M, Sinagra E, Dolcimascolo S, Rizzolo CA, Puccia F, Mocciaro F, Marasà S, Perricone G, **Messina C**, Bedognetti D, Sinagra D. Colorectal Cancer in patients with type2 diabetes: retrospective analysis of 741 cases. *Tumori* 2012

EXPERIENCE IN CLINICAL TRIAL

- Principle investigator for the Expanded access Program for Dostarlimabin d MMR/MSI-H Endometrial cancer
- Principle investigator for the “Single patient Compassionate Use Program with AVELUMAB for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy”
- Principle investigator for the retrospective multicenter national study: Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Meet-URO 15 (I-BIO-REC) study.
- Sub-investigator for the TRITON3 trial: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
- Sub-investigator for the CO39303 trial: A Phase III, randomized, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, relative to Placebo plus Abiraterone plus Prednisone/Prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant Prostate Cancer.
- Sub-investigator for the PROSPER MDV3100-14 trial: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer.
- Sub-investigator for the KEYNOTE-921 trial: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA).

- Sub-investigator for the BAY 15396: A Phase 3, Randomized Double-Blind placebo-controlled TRIAL for radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
- Sub-investigator for the KEYLYNK-010: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy.
- Sub – Investigator for NIVES trial: Nivolumab plus stereotactic body radiotherapy (SBRT) in II and III line of patients with metastatic renal cell carcinoma (m RCC)
- Sub-investigator for PRIME study: Sviluppo del test PRIME per l'identificazione di biomarcatori tramite biopsia liquida (non invasive) in pazienti con tumore alla prostata
- Sub-investigator for the ENGOT-ov43 trial: A Randomized Phase 3, Double-Blind study of Chemotherapy with or without Pembrolizumab followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC).
- Sub-investigator for the 64091742PCR3001 MAGNITUDE trial: A Phase 3 Randomized, Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for First-Line Treatment of Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC) and DNA-Repair Defects.
- Sub-investigator for the TALAPRO-2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
- Sub-investigator for the protocol B9991001: A phase III, multicentre, multinational, randomized, open-label, parallel-arm study of avelumab* (msb0010718c) plus best supportive care versus best supportive care alone in patients who completed first-line chemotherapy for unresectable locally advanced or metastatic urothelial cancer.
- Sub-investigator for the protocol AV-951-15-303 (AVEO Trial): A phase III, Randomized, Controlled, Multi-Center, Open-Label Study to compare Tivozanib Hydrochloride (AV-951) to Sorafenib in Subjects with refractory advanced renal cell carcinoma (2016).
- Sub-investigator for the DANUBE Trial: “A Phase III, Randomized, Open Label, Controlled, Multi Center, Global Study of First-Line MED14736 Monotherapy and MED14736 in combination with Tremelimumab versus standard of care chemotherapy in patients with unresectable Stage IV urothelial bladder cancer” (2016).

REVIEWER FOR THE FOLLOWING JOURNAL:

- Critical Review in Oncology and Hematology
- BMJ
- Future Oncology
- Cancer Management and Research
- World journal of Surgical Oncology

- World Journal of gastroenterology
- Oncotargets and Therapy
- Therapeutic and Clinical Risk Management
- International Medical Case Reports Journal
- Cancer Treatment and research communication

EDITOR FOR THE FOLLOWING JOURNAL:

- Guest editor for Cancers for the special issue: Precision Medicine in Prostate Cancer

REFERENCES:

Orazio Caffo, MD

Prof. Francesco Boccardo

I hereby authorize the treatment of my personal data according to the Italian D.Lgs n.196, 30th June 2003, and GDPR 679/16

Palermo 1/3/22

Carlo Messina

INFORMAZIONI PERSONALI **Zago Giulia**

OCCUPAZIONE DESIDERATA

ESPERIENZA
PROFESSIONALE

18/07/2016–alla data attuale

Oncologo Medico

Istituto Oncologico Veneto, IOV - U.O.C. Oncologia Medica 2, Padova (Italia)

Oncologo Medico con particolare interesse nell'attività clinica e di ricerca nell'ambito dell'oncologia toracica.

01/02/2016–30/06/2016

Specializzando in Oncologia Medica

Università degli Studi di Padova, Istituto Oncologico Veneto, U.O.C. Oncologia Medica 2, Padova (Italia)

Attività clinica e di ricerca clinica in oncologia medica, con particolare interesse nell'ambito dell'Oncologia Toracica.

Attività o settore Oncologia Toracica

01/08/2015–31/01/2016

Specializzando in Oncologia Medica

Netherlands Cancer Institute, Antoni van Leeuwenhoek (NKI-AVL), Amsterdam (Paesi Bassi)

Attività clinica e di ricerca clinica nell'ambito dell'oncologia toracica.

Attività o settore Oncologia Toracica

01/07/2013–30/07/2015

Specializzando in Oncologia Medica

Università degli Studi di Padova, Istituto Oncologico Veneto, U.O.C. Oncologia Medica 2, Padova (Italia)

Attività clinica e di ricerca clinica in Oncologia Medica, in particolare nell'ambito dell'Oncologia Toracica.

Attività o settore Oncologia Toracica

01/01/2013–30/06/2013

Specializzando in Oncologia Medica

Università degli Studi di Padova, Dipartimento di Pediatria, Unità di Oncoematologia Pediatrica, Padova (Italia)

Attività clinica nell'ambito dell'oncologia pediatrica.

Attività o settore Oncoematologia Pediatrica

01/01/2012–31/12/2012

Specializzando in Oncologia Medica

Università degli Studi di Padova

Attività clinica e di ricerca clinica in Oncologia Medica, con particolare interesse nel campo delle patologie del tratto gastroenterico.

Durante questo periodo le attività cliniche e di ricerca sono state condotte presso il reparto di Oncologia Medica 1 dell'Istituto Oncologico Veneto di Padova e presso il reparto di Oncologia dell'Ospedale Santi Giovanni e Paolo di Venezia.

Attività o settore Patologie oncologiche del tratto gastroenterico

30/06/2011–31/12/2011 **Specializzando in Oncologia Medica**
Università degli Studi di Padova, Clinica Medica 5, Padova (Italia)

Attività o settore Medicina Interna

01/07/2010–30/06/2011 **Borsista**
Istituto Oncologico Veneto, U.O.C. Oncologia Medica 2, Padova (Italia)
Attività clinica e di ricerca clinica nell'ambito della patologia oncologica mammaria.

Attività o settore Oncologia senologica

ISTRUZIONE E FORMAZIONE

06/2011–06/2016 **Specializzazione in Oncologia Medica**
Università degli Studi di Padova, Padova (Italia)
Specializzazione conseguita in data 30 giugno 2016, con valutazione finale 110/110 cum laude.

11/2009–02/2010 **Abilitazione professionale**
Iscritta all'ordine dei Medici Chirurghi ed Odontoiatri di Padova.
Licenza medica : PD10529.

10/2003–07/2009 **Laurea specialistica in Medicina e Chirurgia**
Università degli Studi di Padova, Padova (Italia)
Laurea conseguita in data 23 luglio 2009 con valutazione finale di 110/110.

09/1998–06/2003 **Maturità Scientifica**
Liceo Scientifico Ippolito Nievo, Padova (Italia)

COMPETENZE PERSONALI

Lingua madre italiano

Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	B2	B2	B2	B2	B2
olandese	A1	A2	A1	A1	A2

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

ULTERIORI INFORMAZIONI

Esperienza nell'ambito di trial clinici

Esperienza nella gestione di trial clinici.
GCP e study management training completati in data 29 ottobre 2013.

Appartenenza a gruppi / associazioni

Membro di:

- ESMO, European Society of Medical Oncology, da Maggio 2015
- AIOM, Associazione Italiana di Oncologia Medica, da Ottobre 2015

Pubblicazioni

- **Zago G**, Muller M, van den Heuvel M, Baas P. *New targeted treatments for non-small-cell lung cancer - role of nivolumab*. *Biologics* 2016 Aug 1;10:103-17. doi: 10.2147/BTT.S87878
- Bonanno L, **Zago G**, Marulli G, Del Bianco P, Schiavon M, Pasello G, Polo V, Canova F, Tonetto F, Loreggian L, Rea, F, Conte PF, Favaretto A. *Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment*. *Onco Targets and Therapy*, 2016;9: 3671-3681
- Polo V, **Zago G**, Frega S, Canova F, Bonanno L, Favaretto A, Bonaldi L, Bertorelle R, Conte P F, Pasello G. *Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature*. *Am J Case Rep* 2015; Nov 3;16:782-9.
- Pasello G, Carli P, Canova F, Bonanno L, Polo V, **Zago G**, Urso L, Conte P F, Favaretto A. *Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer*. *Anticancer Research* 2015; 35:2183-2190.
- Evangelista L, Redana S, Racca M, Geuna E, Vinante L, **Zago G**, De Carolis V, Ghiotto C, Saladini G, Varetto T. *FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer*. *Clin Nucl Med* 2014 Feb;39(2):e135-41. doi: 10.1097/RLU.0b013e318287353e.

Autorizzo il trattamento dei miei dati personali in base al D. Lgs 196/2003.